Botanix has now successfully completed its first acne patient studies with BTX 1503 and is preparing for a Phase 2 study in Q2 2018, while concurrently completing a Phase 1b study for BTX 1204 in atopic dermatitis patients.
The Company has an exclusive license to use a proprietary drug delivery system (PermetrexTM) for direct skin delivery of active pharmaceuticals in all skin diseases and plans to progress the development of BTX 1503, BTX 1204 and its pipeline of other PermetrexTM enabled products alone, or in collaboration with partners.
The positive results are going to catapult the SP this Quarter to new highs, "Disclosure" I have loaded up my Tonka truck awaiting the news....
Big News Coming for the Patient
-
- There are more pages in this discussion • 148 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
0.010(2.41%) |
Mkt cap ! $770.9M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 42.5¢ | 41.0¢ | $1.317M | 3.136M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 326888 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 727097 | 15 |
View Market Depth
| Last trade - 13.55pm 06/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |